Group by Gene: | RANK ligand inhibitor denosumab | Bcr-abl tyrosine kinase inhibitor nilotinib | Topoisomerase II inhibitor, EGFR inhibitor gefitinib + mitoxantrone | CSF-1R inhibitor, c-KIT inhibitor, FLT3 inhibitor, AKT inhibitor, FMS kinase inhibitor pexidartinib |
---|---|---|---|---|
No biomarker | ||||
COL6A3-CSF1 fusion | ||||
H3F3A mutation + ARID2 mutation |